Zobrazeno 1 - 10
of 52
pro vyhledávání: '"William N. Malatestinic"'
Autor:
Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 451-464 (2024)
Abstract Background Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 mon
Externí odkaz:
https://doaj.org/article/5609bda68fd54de38cb6383ba4e84d38
Autor:
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1615-1631 (2024)
Abstract Introduction Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRIT-P1 (NCT01695239)
Externí odkaz:
https://doaj.org/article/3d639bca47a94f48a215a9ee1b30d788
Autor:
April Armstrong, Alvaro González-Cantero, Saakshi Khattri, Guilherme Muzy, William N. Malatestinic, Anastasia Lampropoulou, Meghan Feely, Sophia Kyoungah See, Can Mert, Andrew Blauvelt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 933-952 (2024)
Abstract Introduction The National Psoriasis Foundation (NPF) recommends evaluating patient response to treatment at week 12, with a target response of ≤ 1% body surface area (BSA) affected by plaque psoriasis and an acceptable response of BSA ≤
Externí odkaz:
https://doaj.org/article/18ad757c729640a0a3d9647ce3646604
Autor:
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2297-2297 (2024)
Externí odkaz:
https://doaj.org/article/f91b6b4a3b6c43909bb9dc902b073355
Autor:
Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1831-1846 (2023)
Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s pers
Externí odkaz:
https://doaj.org/article/114f099f9c514b8f96ecb4ac00b347b4
Autor:
William Benjamin Nowell, Kelly Gavigan, Theresa Hunter, William N. Malatestinic, Rebecca J. Bolce, Jeffrey R. Lisse, Carol Himelein, Jeffrey R. Curtis, Jessica A. Walsh
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 1, Pp 85-94 (2022)
Objective Aims were to 1) to characterize patient decision‐making with treatment for axial spondyloarthritis (axSpA) and 2) to explore relationships among decision‐making, treatment satisfaction, and biologic disease modifying antirheumatic drugs
Externí odkaz:
https://doaj.org/article/dcd47077d46f40c2ba328ce9c1afb065
Autor:
Ana-Maria Orbai, Julie A. Birt, Elizabeth A. Holdsworth, Nicola Booth, William N. Malatestinic, Aubrey T. Sprabery, Anthony M. Reginato
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 4, Pp 937-948 (2020)
Abstract Introduction Enthesitis is a core outcome domain assessed in psoriatic arthritis (PsA) clinical trials. Limited evidence describes the impact of enthesitis on patient-reported outcomes (PROs) and physician satisfaction with current treatment
Externí odkaz:
https://doaj.org/article/c167ec2cfc9247df933f486e289aa221
Autor:
Benjamin, Lockshin, Ryan W, Harrison, Robert R, McLean, Margaux M, Crabtree, Bruce W, Konicek, Baojin, Zhu, William N, Malatestinic, Bilal, Atiya, Mwangi J, Murage, Russel T, Burge
Publikováno v:
Dermatology and Therapy. 12:2797-2815
The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and compare the effectiveness of ixekizumab between patients who previously failed secukinumab and those who
Autor:
Craig, Leonardi, Baojin, Zhu, William N, Malatestinic, William J, Eastman, Jiaying, Guo, Mwangi J, Murage, Casey Kar-Chan, Choong, Russel, Burge, Andrew, Blauvelt
Publikováno v:
Advances in Therapy. 39:3214-3224
Limited real-world data are available comparing multiple biologics on their adherence, persistence, and the use of concomitant biologics in the treatment of moderate-to-severe psoriasis in clinical practice. The objective was to compare persistence o
Autor:
Kelly Gavigan, W. Benjamin Nowell, Theresa Hunter, Jeffrey R. Curtis, William N. Malatestinic, Rebecca J. Bolce, Jeffrey R. Lisse, Jessica Walsh
Publikováno v:
Rheumatology and Therapy. 9:663-677
The aim of this study was to characterize employment, work productivity, and biologic disease-modifying anti-rheumatic drug (bDMARD) treatment in a predominantly female population of axial spondyloarthritis (axSpA) patients in a real-world setting.Th